Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is set to present new preclinical data on TNX-801, its recombinant horsepox virus live vaccine candidate, at the Vaccine Congress 2025 in Vienna on July 10. The presentation, to be delivered by Dr. Sina Bavari, Executive Vice President of Infectious Disease Research and Development, will focus on the vaccine’s protective efficacy against mpox and other orthopoxviruses in animal models following a single dose. This development is significant as it underscores the potential of TNX-801 to induce durable immune responses, offering a promising solution to current and emerging viral threats.

The data to be presented includes findings on the safety, immunogenicity, and efficacy of TNX-801, along with the company’s plans to initiate clinical trials. This step is crucial in the vaccine’s development pathway, as it moves closer to potential human testing and eventual deployment. The platform’s design allows for expansion to target other viral threats, highlighting its versatility and importance in the global effort to combat infectious diseases.

Tonix Pharmaceuticals’ commitment to addressing public health challenges is further evidenced by its state-of-the-art infectious disease research facility in Frederick, Maryland, and its GMP-capable advanced manufacturing facility in Dartmouth, Maryland. These facilities are poised to support the production of TNX-801, especially in response to national or international emergencies. The company’s focus on transforming therapies for pain management and modernizing solutions for public health challenges positions it as a key player in the biopharmaceutical industry.

The presentation at the Vaccine Congress 2025 represents a significant milestone for Tonix Pharmaceuticals and the broader scientific community. It not only showcases the potential of TNX-801 as a vaccine candidate but also highlights the importance of innovative research and development in addressing global health challenges. For more information on Tonix Pharmaceuticals and its initiatives, visit https://www.TonixPharma.com.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Tonix Pharmaceuticals to Showcase TNX-801 Mpox Vaccine Data at Vaccine Congress 2025.